Jade Biosciences (JBIO)

• Market cap: $451M
• 1 day: -0.51%
• 5 days: -2.49%
• 1 month: 13.56%
• 3 months: 36.3%
• 6 months: 3.16%
• Year to date: -89.59%
• 1 year: -88.57%
• 5 years: -98.77%
• 10 years: -98.77%
• Sector: Healthcare
• Industry: Biotechnology

About: Jade Biosciences Inc is focused on developing therapies to address critical unmet needs in autoimmune diseases. Its asset, JADE-001, will target the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for immunoglobulin A (IgA) nephropathy, with Investigational New Drug Application-enabling studies underway and initiation of a first-in-human trial. Jade's pipeline also includes two undisclosed optimized antibody discovery programs, JADE-002 and JADE-003, currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount.